These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 20696662)

  • 41. Impact of Body Mass Index, Age, Prostate Volume, and Genetic Polymorphisms on Prostate-specific Antigen Levels in a Control Population.
    Cornu JN; Cancel-Tassin G; Cox DG; Roupret M; Koutlidis N; Bigot P; Valeri A; Ondet V; Gaffory C; Fournier G; Azzouzi AR; Cormier L; Cussenot O
    Eur Urol; 2016 Jul; 70(1):6-8. PubMed ID: 26850968
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association of KLK3 (PSA) genetic variants with prostate cancer risk and PSA levels.
    Penney KL; Schumacher FR; Kraft P; Mucci LA; Sesso HD; Ma J; Niu Y; Cheong JK; Hunter DJ; Stampfer MJ; Hsu SI
    Carcinogenesis; 2011 Jun; 32(6):853-9. PubMed ID: 21421545
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cysteine-rich secretory protein 3 and β-microseminoprotein on prostate cancer needle biopsies do not have predictive value for subsequent prostatectomy outcome.
    Hoogland AM; Dahlman A; Vissers KJ; Wolters T; Schröder FH; Roobol MJ; Bjartell AS; van Leenders GJ
    BJU Int; 2011 Oct; 108(8):1356-62. PubMed ID: 21410630
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen.
    Nam RK; Diamandis EP; Toi A; Trachtenberg J; Magklara A; Scorilas A; Papnastasiou PA; Jewett MA; Narod SA
    J Clin Oncol; 2000 Mar; 18(5):1036-42. PubMed ID: 10694554
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development of sensitive immunoassays for free and total human glandular kallikrein 2.
    Väisänen V; Eriksson S; Ivaska KK; Lilja H; Nurmi M; Pettersson K
    Clin Chem; 2004 Sep; 50(9):1607-17. PubMed ID: 15247158
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy.
    Bjartell AS; Al-Ahmadie H; Serio AM; Eastham JA; Eggener SE; Fine SW; Udby L; Gerald WL; Vickers AJ; Lilja H; Reuter VE; Scardino PT
    Clin Cancer Res; 2007 Jul; 13(14):4130-8. PubMed ID: 17634540
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival.
    Li W; Middha M; Bicak M; Sjoberg DD; Vertosick E; Dahlin A; Häggström C; Hallmans G; Rönn AC; Stattin P; Melander O; Ulmert D; Lilja H; Klein RJ
    Eur Urol; 2018 Dec; 74(6):710-719. PubMed ID: 30289108
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Early prediction of prostate cancer biochemical recurrence and identification of disease persistence using PSA isoforms and human kallikrein-2.
    Do Carmo Silva J; Vesely S; Luksanova H; Prusa R; Babjuk M
    Tumour Biol; 2021; 43(1):197-207. PubMed ID: 34486998
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target.
    Whitaker HC; Warren AY; Eeles R; Kote-Jarai Z; Neal DE
    Prostate; 2010 Feb; 70(3):333-40. PubMed ID: 19790236
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Genome-wide association study identified novel genetic variant on SLC45A3 gene associated with serum levels prostate-specific antigen (PSA) in a Chinese population.
    Sun J; Tao S; Gao Y; Peng T; Tan A; Zhang H; Yang X; Qin X; Hu Y; Feng J; Kim ST; Lin X; Wu Y; Zhang J; Li Z; Li L; Mo L; Liang Z; Shi D; Huang Z; Huang X; Liu M; Liu Q; Zhang S; Lilly Zheng S; Xu J; Mo Z
    Hum Genet; 2013 Apr; 132(4):423-9. PubMed ID: 23269536
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
    Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
    J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients.
    Kurek R; Nunez G; Tselis N; Konrad L; Martin T; Roeddiger S; Aumüller G; Zamboglou N; Lin DW; Tunn UW; Renneberg H
    Clin Cancer Res; 2004 Sep; 10(17):5808-14. PubMed ID: 15355910
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Validation of association of genetic variants at 10q with prostate-specific antigen (PSA) levels in men at high risk for prostate cancer.
    Chang BL; Hughes L; Chen DY; Gross L; Ruth K; Giri VN
    BJU Int; 2014 May; 113(5b):E150-6. PubMed ID: 23937305
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prostate-specific antigen (hK3) and human prostatic glandular kallikrein (hK2) in the detection of early stage human prostate cancer.
    Wilson MJ
    J Lab Clin Med; 1998 Apr; 131(4):298-9. PubMed ID: 9579381
    [No Abstract]   [Full Text] [Related]  

  • 55. Simultaneous quantification of prostate-specific antigen and human glandular kallikrein 2 mRNA in blood samples from patients with prostate cancer and benign disease.
    Ylikoski A; Pettersson K; Nurmi J; Irjala K; Karp M; Lilja H; Lövgren T; Nurmi M
    Clin Chem; 2002 Aug; 48(8):1265-71. PubMed ID: 12142383
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of increasing the PSA cutoff to perform additional biomarker tests before prostate biopsy.
    Nordström T; Adolfsson J; Grönberg H; Eklund M
    BMC Urol; 2017 Oct; 17(1):92. PubMed ID: 28974201
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.
    Lilja H; Ulmert D; Björk T; Becker C; Serio AM; Nilsson JA; Abrahamsson PA; Vickers AJ; Berglund G
    J Clin Oncol; 2007 Feb; 25(4):431-6. PubMed ID: 17264339
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Simultaneous quantification of human glandular kallikrein 2 and prostate-specific antigen mRNAs in peripheral blood from prostate cancer patients.
    Ylikoski A; Karp M; Pettersson K; Lilja H; Lövgren T
    J Mol Diagn; 2001 Aug; 3(3):111-22. PubMed ID: 11486050
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer.
    Haese A; Becker C; Noldus J; Graefen M; Huland E; Huland H; Lilja H
    J Urol; 2000 May; 163(5):1491-7. PubMed ID: 10751864
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predictive value of kallikrein forms and β-microseminoprotein in blood from patients with evidence of detectable levels of PSA after radical prostatectomy.
    Pellegrino F; Sjoberg DD; Tin AL; Benfante NE; Briganti A; Montorsi F; Scardino PT; Eastham JA; Vickers AJ; Lilja H; Laudone VP
    World J Urol; 2023 Jun; 41(6):1489-1495. PubMed ID: 37209144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.